2026-07-05 · medications, saxenda, liraglutide, GLP-1, obesity medicine, adolescent obesity, prescription · 19 min read

How much weight loss should I actually expect on Saxenda?

In the pivotal 56-week SCALE Obesity and Prediabetes trial (Pi-Sunyer 2015, New England Journal of Medicine), 3,731 adults with BMI ≥ 30 (or ≥ 27 with a weight-related comorbidity) on liraglutide 3.0 mg lost a mean of 8.0% of baseline body weight versus 2.6% on placebo, and 63% lost at least 5%. SCALE Diabetes (Davies 2015, JAMA) in 846 adults with type 2 diabetes reproduced a 6.0% versus 2.0% result and lowered A1c by 1.3% versus 0.3%. SCALE Sleep Apnea (Blackman 2016, International Journal of Obesity) added 5.7% versus 1.6% at 32 weeks with a 12.2-event/hr AHI reduction. Honest positioning: the head-to-head STEP-8 trial (Rubino 2021, JAMA) randomised 338 adults directly to semaglutide 2.4 mg versus liraglutide 3.0 mg, and at 68 weeks the numbers were 15.8% versus 6.4% — Saxenda delivers roughly 40% of Wegovy's effect and, by cross-trial comparison with SURMOUNT-1 (Jastreboff 2022, NEJM: tirzepatide 15 mg produced 22.5% at 72 weeks), roughly 30% of Zepbound's effect.

Why does Saxenda still matter now that Wegovy and Zepbound exist?

Three reasons. First, adolescents. The Ellipse trial (Kelly 2020, NEJM) randomised 251 adolescents 12–17 with obesity to liraglutide 3.0 mg versus placebo and reported a 4.29% BMI reduction versus 0.29% at 56 weeks — the data that grounded the 2020-12 FDA extension. Saxenda is the only GLP-1 FDA-approved for adolescent obesity down to age 12, and the AAP 2023 Clinical Practice Guideline for pediatric obesity lists it as a pharmacotherapy consideration for that age group. Second, access. When Wegovy or Zepbound are back-ordered, denied by insurance, or contraindicated, Saxenda often has broader payer coverage and steadier supply — a real ~6–8% weight-loss drug is meaningfully better than no drug. Third, the longest post-approval safety record. Liraglutide has been on the US market since 2010 (as Victoza at 1.8 mg for type 2 diabetes) and since 2014-12 as Saxenda at 3.0 mg for obesity, and the LEADER cardiovascular outcome trial (Marso 2016, NEJM) in 9,340 adults with T2D and cardiovascular risk reported a 13% reduction in 3-point MACE and a 15% reduction in all-cause mortality over 3.8 years — CV signal that carries over conceptually to the 3.0 mg obesity dose.

What is the difference between Saxenda and Wegovy?

Same drug class (GLP-1 receptor agonists), different molecule, different dosing schedule, and — in the one head-to-head trial — very different weight-loss magnitude. Saxenda is liraglutide 3.0 mg injected subcutaneously once daily. Wegovy is semaglutide 2.4 mg injected subcutaneously once weekly. Structurally, liraglutide shares 97% homology with native GLP-1 while semaglutide shares 94% — the smaller structural change in liraglutide is why its receptor binding is weaker and its half-life is much shorter (roughly 13 hours vs roughly one week for semaglutide; Nauck 2020, Diabetes Obesity Metabolism). The STEP-8 head-to-head (Rubino 2021, JAMA) delivered the definitive comparison: 15.8% weight loss on semaglutide versus 6.4% on liraglutide at 68 weeks — a roughly 2.5-fold difference. For most adults where both drugs are accessible and tolerated, Wegovy is the preferred choice; Saxenda holds ground in adolescents 12+, in access-limited situations, and when a shorter-half-life agent is deliberately preferred (e.g. to enable faster washout if adverse events arise).

How is Saxenda dosed and titrated?

Saxenda is titrated weekly over 4 to 5 weeks to minimize nausea, vomiting, and diarrhoea. Week 1: 0.6 mg once daily. Week 2: 1.2 mg. Week 3: 1.8 mg. Week 4: 2.4 mg. Week 5 and beyond: 3.0 mg once daily — the maintenance dose. Inject subcutaneously into the abdomen, thigh, or upper arm at roughly the same time each day; timing relative to meals does not matter. If GI symptoms are limiting, hold at the current dose for an extra week or step back one dose rather than abandoning the drug — the Bettge 2017 meta-analysis (Diabetes Obesity Metabolism) showed nausea affects roughly 40% of patients during titration but resolves by weeks 8–12 in most. The FDA week-16 stop rule (FDA 2014 labelling): if you have not lost at least 4% of baseline body weight by week 16 on the 3.0 mg maintenance dose, discontinue — continued use is unlikely to produce clinically meaningful weight loss and unnecessarily exposes you to the drug's side-effect profile and injection burden.

Can Saxenda be prescribed for adolescents?

Yes, and it is the only GLP-1 receptor agonist that carries a formal FDA obesity approval for adolescents (age 12–17). The pivotal Ellipse trial (Kelly 2020, NEJM) randomised 251 adolescents to liraglutide 3.0 mg versus placebo and reported a 4.29% BMI reduction versus 0.29% at 56 weeks, with a side-effect profile broadly similar to the adult SCALE trials. The FDA extended Saxenda's indication to adolescents 12+ with weight greater than 60 kg and BMI at or above the 95th percentile in December 2020. The AAP 2023 Clinical Practice Guideline for the evaluation and treatment of pediatric obesity lists pharmacotherapy as a consideration for adolescents 12+, and Saxenda is the GLP-1 anchor of that recommendation. Semaglutide (Wegovy) received an adolescent extension in 2022 for age 12+, but as of 2026 Saxenda retains the longest safety record in this population and remains the most common first-line GLP-1 prescribed for adolescents when the family is comfortable with a daily injection.

What are the most common side effects?

The Bettge 2017 GI events meta-analysis (Diabetes Obesity Metabolism) pooled the SCALE and adjacent trials and reported nausea in roughly 40% of patients during titration, vomiting in roughly 16%, and diarrhoea in roughly 21% — most resolving by weeks 8–12. Constipation, dyspepsia, headache, injection-site reactions, and mild-to-moderate fatigue are common. Rare but serious signals: pancreatitis (persistent severe abdominal pain radiating to the back with vomiting is a 911-level workup), gallbladder disease (biliary colic in the setting of rapid weight loss), acute kidney injury from dehydration if vomiting is severe, and — carried across from the drug label based on rodent thyroid C-cell tumour signal — a boxed contraindication in personal or family history of medullary thyroid carcinoma or MEN2. Suicidal ideation is a smaller signal watched across the GLP-1 class; new or worsening mood changes warrant clinician contact and 988 crisis-line access in acute cases. Slow titration, hydration, small frequent meals, avoiding high-fat and high-sugar meals during dose escalation, and prokinetic strategies are the standard tolerability toolkit (Gorgojo-Martínez 2023, Journal of Clinical Medicine).

What is the FDA week-16 stop rule?

The FDA 2014 Saxenda labelling requires reassessment at week 16 on the 3.0 mg maintenance dose. If less than 4% of baseline body weight has been lost by that point, the drug should be discontinued because continued use is unlikely to produce clinically meaningful weight loss. This stop rule exists because the SCALE-trial responder analyses showed that patients who had not achieved 4% loss by week 16 rarely reached the 5–10% threshold by week 56. The parallel FDA stop rules for the other approved obesity drugs are similar in spirit: Wegovy at 5% by 68 weeks in Wilding 2021, Contrave at 5% by week 16, Qsymia at 3% by week 12 on the 7.5/46 mg dose. Discontinuing at the stop-rule assessment is not a failure — it is the labelled and evidence-based decision when the drug is not delivering, and it frees the patient to try a different agent or approach.

How should I plan for stopping Saxenda?

Plan for it at the start of treatment, not at the end. Aroda 2019 (Diabetes Obesity Metabolism) and the STEP-4 semaglutide discontinuation data (Rubino 2021, JAMA) together show that roughly two-thirds of the weight lost on a GLP-1 typically returns within 12 months of stopping — because appetite regulation reverts, gastric emptying resumes at baseline speed, and the reward-value of highly palatable foods returns. The muscle mass lost during weight loss (roughly 25–40% of total lost weight in most GLP-1 trials) does not automatically return; body composition can drift toward higher fat percentage even at a partially recovered weight. Muscle-preserving resistance training, deliberate protein intake (roughly 1.2–1.6 g/kg body weight per day), and continued behavioural scaffolding through the transition are the standard toolkit. If the plan is chronic therapy rather than a defined stop, discuss it explicitly with your prescriber; if the plan is to stop, taper is not required (there is no withdrawal syndrome) but continuing the behavioural infrastructure that supported the loss is essential.

Can I switch from Saxenda to Wegovy or Zepbound?

Yes, and no washout period is required. The standard practice is to discontinue Saxenda after the last daily dose and start Wegovy at the 0.25 mg starting dose (semaglutide 2.4 mg's own 5-step titration) or Zepbound at 2.5 mg (tirzepatide's own titration) the following week. Do not attempt to jump straight to a higher starting dose of the new agent — the titration schedules exist to manage GI tolerability, and skipping steps produces avoidable nausea. Tell patients that the injection frequency changes from daily to weekly, that GI symptoms may return during the new drug's titration even after they resolved on Saxenda (the receptor pharmacology is different enough that tolerance does not cross fully), and that the expected weight-loss magnitude will be substantially higher on either newer agent. Switching in the opposite direction (Wegovy or Zepbound back to Saxenda) is unusual and typically driven by access or tolerability constraints rather than efficacy preference.

Saxenda (Liraglutide 3 mg) for Weight Loss: Where the First FDA-Approved GLP-1 Fits After Wegovy and Zepbound

Quick stats

• Mean weight loss at 56 weeks on 3.0 mg (Pi-Sunyer 2015 SCALE Obesity, NEJM): 8.0% on liraglutide vs 2.6% on placebo — 63% of patients lost at least 5%.
• STEP-8 head-to-head vs semaglutide 2.4 mg (Rubino 2021, JAMA): 15.8% on semaglutide vs 6.4% on liraglutide at 68 weeks — Saxenda delivers roughly 40% of Wegovy’s effect and, by cross-trial comparison with SURMOUNT-1, roughly 30% of Zepbound’s.
• Adolescent BMI reduction at 56 weeks (Kelly 2020 Ellipse, NEJM): −4.29% BMI on liraglutide vs −0.29% on placebo — the pivotal data behind the 2020-12 FDA extension for adolescents 12+.
• GI titration side-effect rates (Bettge 2017 meta-analysis, Diabetes Obesity Metabolism): nausea ~40%, vomiting ~16%, diarrhoea ~21% — most resolving by weeks 8–12.
• 24-month real-world persistence (Wharton 2020 Canadian cohort, Diabetes Obesity Metabolism): ~15% — daily-injection burden and cost are the two largest drivers of discontinuation.
• Emergency red flag: persistent right-upper-quadrant abdominal pain, unremitting vomiting, or radiating epigastric pain — pancreatitis workup; call 911 if severe or with fever; poison control 1-800-222-1222 for over-injection.

The honest picture, in one paragraph

Saxenda produces roughly 6–8% weight loss on average at 56 weeks (Pi-Sunyer 2015 SCALE Obesity; Davies 2015 SCALE Diabetes) — real, clinically meaningful, and the FDA benchmark that started the modern obesity-drug era in 2014. But head-to-head against semaglutide 2.4 mg (Wegovy), the STEP-8 trial (Rubino 2021, JAMA) puts Saxenda at roughly 40% of Wegovy’s effect (6.4% vs 15.8% at 68 weeks), and by cross-trial comparison with SURMOUNT-1 (Jastreboff 2022, NEJM: tirzepatide 15 mg produced 22.5% at 72 weeks) roughly 30% of Zepbound’s. It still carries three legitimate roles in 2026: the only GLP-1 FDA-approved for adolescents 12+ (Ellipse trial, Kelly 2020, NEJM; FDA 2020-12 extension); a legitimate option when semaglutide and tirzepatide are back-ordered, uncovered, or contraindicated; and the drug with the longest post-approval real-world safety experience in the GLP-1 class. The daily-injection burden and GI tolerability during titration are the two biggest reasons patients discontinue — 24-month real-world persistence is roughly 15% in the Wharton 2020 Canadian cohort — and honest counselling at the start of therapy matters as much as any titration decision downstream.

How Saxenda fits into the FDA-approved obesity drug lineup

The 2026 US obesity-medicine armamentarium centres on five FDA-approved chronic-weight-management drugs. Saxenda is the oldest of the GLP-1s and the smallest in effect size, but retains the only adolescent indication.

Why liraglutide works (and does not work as well as newer GLP-1s)

Four mechanistic threads explain both what Saxenda does and why it delivers less than semaglutide or tirzepatide.

1. GLP-1 receptor agonism at the hypothalamic arcuate nucleus

Liraglutide binds and activates the GLP-1 receptor on pro-opiomelanocortin (POMC) neurons in the hypothalamic arcuate nucleus (ARC), which drives satiety through α-melanocyte-stimulating hormone release. It also delays gastric emptying (prolonging post-meal fullness) and enhances glucose-dependent insulin secretion (Meier 2017, Nature Reviews Endocrinology). These are the same three mechanisms that semaglutide and tirzepatide share — the difference is potency and duration at the receptor.

2. Half-life of ~13 hours — daily injection required

Liraglutide’s serum half-life is roughly 13 hours (Nauck 2020, Diabetes Obesity Metabolism), which is why once-daily subcutaneous injection is required. Semaglutide’s half-life is roughly 1 week and tirzepatide’s is roughly 5 days, both enabling weekly dosing. The daily injection burden is the most-cited reason for discontinuation in real-world Saxenda cohorts (Wharton 2020; Kushner 2020), and a higher peak-to-trough ratio at each daily dose contributes to nausea at the dose peak in a way weekly agents do not replicate.

3. 97% homology to native GLP-1 vs semaglutide’s 94%

Liraglutide is structurally closer to native human GLP-1 (97% homology) than semaglutide (94% homology; Nauck 2020). The smaller structural change is why liraglutide is more rapidly degraded by dipeptidyl peptidase-4 (DPP-4), why its receptor binding is weaker, and why its duration is shorter. Semaglutide’s additional structural modifications extend its half-life and increase its receptor affinity — which is a meaningful part of why STEP-8 (Rubino 2021) delivered a 2.5-fold weight-loss advantage over liraglutide.

4. What Saxenda is not

Saxenda is not a first-choice drug for adults when Wegovy or Zepbound are accessible, tolerated, and covered. It is not a T2D-first-line drug — Victoza (liraglutide 1.8 mg) is the T2D indication, and semaglutide (Ozempic) is the more effective T2D-indicated GLP-1. It is not appropriate as a stand-alone drug with no lifestyle scaffolding — the SCALE trials embedded a structured 500 kcal/day deficit and behavioural counselling in every arm, and the effect size reported in the label assumes that scaffolding.

Titration schedule

Saxenda’s titration is designed to escalate weekly through five doses over 4 to 5 weeks. The most common tolerability failure is stepping up too aggressively despite ongoing nausea; the standard rescue is to hold at the current dose or step back one dose for another week rather than to stop the drug (Gorgojo-Martínez 2023, Journal of Clinical Medicine).

The 3.0 mg maintenance dose is the labelled dose for the obesity indication and the dose at which all SCALE-trial efficacy estimates apply. Doses of 1.8 mg or lower correspond to the Victoza (T2D) indication and are not expected to deliver Saxenda-level weight loss.

Dose-response and time-course

The trajectory of weight loss on liraglutide 3.0 mg is roughly linear through week 24, with a plateau approaching week 56 and — in extension data — modest additional loss to 24 months for patients who remain on the drug. The Ellipse adolescent trajectory is slower in absolute terms because BMI is the outcome (Kelly 2020, NEJM).

5-step Saxenda protocol

This is the pathway that matches FDA 2014 labelling (with the 2020-12 adolescent extension), the AACE 2016 Obesity Clinical Practice Guideline (Garvey), the ADA 2024 Standards of Care Section 8, and the AAP 2023 Clinical Practice Guideline for pediatric obesity.

Step 1: Confirm the indication

Adults: BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, or type 2 diabetes). Adolescents 12–17: weight > 60 kg AND BMI at or above the 95th percentile for age and sex (FDA 2020-12 extension). Use the BMI calculator if you need to confirm.

Step 2: Screen for exclusions

Absolute contraindications and important precautions before prescribing:

• Personal or family history of medullary thyroid carcinoma or MEN2 (boxed contraindication carried from Victoza labelling — rodent thyroid C-cell tumour signal that has not been reproduced in human data but remains the labelled contraindication).
• Pregnancy — discontinue when pregnancy is confirmed; no adequate human data.
• Severe GI disease including gastroparesis — delayed gastric emptying compounds the underlying pathology.
• Active pancreatitis or history of pancreatitis — GLP-1 receptor agonists are contraindicated in active disease and are a precaution in prior disease.
• Severe hepatic impairment — limited data.
• Concurrent GLP-1 or GLP-1/GIP therapy (Wegovy, Ozempic, Zepbound, Mounjaro) — do not stack.

Step 3: Baseline labs and vitals

Standard workup: HbA1c (rule out unrecognised diabetes; changes the drug-selection conversation), lipase (baseline for pancreatitis surveillance), basic metabolic panel including renal function. Document baseline weight, waist circumference, and — for adolescents — BMI-for-age percentile. Baseline PHQ-9 or equivalent mood screen is a class-standard precaution for GLP-1s. Document any personal or family history of medullary thyroid cancer, MEN2, pancreatitis, or gallbladder disease.

Step 4: Titrate weekly from 0.6 to 3.0 mg

Weekly step-ups over 4 to 5 weeks per the titration table above. Injection site rotation (abdomen, thigh, upper arm) reduces injection-site reactions. Common patient counselling points: expect nausea during titration; small low-fat meals; hydration is essential to avoid AKI from vomiting; alcohol and high-fat meals aggravate GI symptoms; the daily injection cadence is intentional (do not skip and double up).

Step 5: Assess at week 16 — the FDA stop rule

At week 16 on the 3.0 mg maintenance dose, reweigh. If less than 4% of baseline body weight has been lost, discontinue Saxenda per FDA 2014 labelling — continued exposure is not justified when the responder threshold has not been met. If 4% or more has been lost, continuing therapy is reasonable, with ongoing lipase and PHQ-9 monitoring at each visit and follow-up at 6 and 12 months. There is no formal FDA taper requirement (no withdrawal syndrome) but the discontinuation-and-regain conversation should be part of the visit at every stop point (see the special-situation section below).

What treatments actually do — comparison

Special situations

Adolescents 12–17

Saxenda is the only GLP-1 FDA-approved with a formal obesity indication for this age group and remains the most commonly prescribed GLP-1 for adolescents in 2026. The Ellipse trial (Kelly 2020, NEJM) enrolled 251 adolescents 12–17 with obesity, randomised to liraglutide 3.0 mg versus placebo for 56 weeks, and reported a BMI reduction of 4.29% versus 0.29% — with a side-effect profile broadly similar to the adult SCALE trials. The AAP 2023 Clinical Practice Guideline for pediatric obesity lists pharmacotherapy as a consideration for adolescents 12+, and Saxenda is the GLP-1 anchor of that recommendation. Parent-plus-adolescent shared decision-making is standard: honest conversation about the daily injection burden (higher friction for adolescents than for adults), realistic expectations for a ~4% BMI reduction rather than a dramatic transformation, and the importance of preserving muscle-building activity through active growth. See adolescent and teen weight management for the broader picture.

Type 2 diabetes with obesity

Liraglutide is available at two doses under two brand names: Victoza 1.8 mg for type 2 diabetes and Saxenda 3.0 mg for chronic weight management. In patients with T2D and obesity who need both indications, the Saxenda 3.0 mg dose covers both — SCALE Diabetes (Davies 2015, JAMA) reported a 6.0% weight reduction and a 1.3% A1c reduction at 56 weeks. Layering onto metformin, an SGLT2 inhibitor, or basal insulin is standard practice; the T2D preferred alternative is semaglutide (Ozempic at the T2D dose or Wegovy at the obesity dose), which the AACE and ADA guidelines both favour when access allows. See diabetes and weight loss, metformin and weight, and SGLT2 inhibitors and weight for the broader picture.

When Wegovy or Zepbound are unavailable

Supply gaps, insurance denials, and formulary restrictions are common realities in 2026. Saxenda often has broader payer coverage (a longer time on the US market and steadier supply) and functions as a legitimate second-choice GLP-1 when the first-choice weekly agents are inaccessible. The counselling frame is honest: patients switching from Wegovy or Zepbound to Saxenda will typically lose roughly 40–50% of the weight-loss magnitude they had on the newer agent, and the injection frequency changes from weekly to daily. Discussing the trade-off openly at the point of switch — rather than hoping the patient will not notice a slower trajectory — protects adherence and trust.

Sleep apnea with obesity

SCALE Sleep Apnea (Blackman 2016, International Journal of Obesity) enrolled 359 adults with moderate-to-severe OSA and reported a 5.7% weight reduction vs 1.6% on placebo at 32 weeks, with a 12.2-events/hr AHI reduction vs 6.1 on placebo. Liraglutide 3.0 mg is a reasonable adjunct to CPAP in weight-associated OSA — the drug is not a CPAP replacement, and the AHI reduction is meaningful but not curative. See sleep apnea and weight loss if the article exists in your reading list.

Post-bariatric with weight regain

Retrospective post-bariatric data suggest 5–7% additional weight loss on Saxenda in patients who have plateaued or begun regain after sleeve gastrectomy or gastric bypass. Off-label but reasonable when Wegovy or Zepbound are unavailable; the injection burden is a real barrier in this population, where daily-injection fatigue often layers onto surgical-follow-up fatigue. See bariatric surgery revision for the surgical-side framing.

Switching Saxenda → Wegovy or Zepbound

No washout period is required. Discontinue Saxenda after the last daily dose, and start Wegovy at 0.25 mg (semaglutide 2.4 mg’s own 5-step titration) or Zepbound at 2.5 mg (tirzepatide’s own titration) the following week. Do not attempt to skip titration steps on the newer agent — the tolerability schedules exist for the same reason Saxenda’s does. Tell the patient: the injection frequency changes from daily to weekly, GI symptoms may return during the new drug’s titration (receptor pharmacology differs enough that cross-tolerance is incomplete), and the expected weight-loss magnitude will be substantially higher on either newer agent.

Discontinuation and weight regain

Roughly two-thirds of weight lost on a GLP-1 typically returns within 12 months of stopping (Aroda 2019, Diabetes Obesity Metabolism; consistent with the semaglutide STEP-4 discontinuation data, Rubino 2021, JAMA). Plan for this at the start, not at the end. Muscle-preserving resistance training, deliberate protein intake, and continued behavioural infrastructure through the transition matter more than any taper protocol. See rebound weight gain after stopping GLP-1 for the broader picture.

Red flags — when to call for help

Some symptoms on Saxenda are not routine and warrant same-day evaluation or emergency care.

• Persistent right-upper-quadrant or radiating epigastric pain with vomiting — pancreatitis or gallbladder disease workup; call 911 if severe, if pain is unremitting, or with fever.
• New neck lump, hoarseness, or dysphagia — thyroid nodule evaluation; medullary thyroid carcinoma is the labelled contraindication and any new neck finding warrants urgent workup.
• Severe dehydration from vomiting (low urine output, dizziness on standing, confusion) — urgent evaluation; risk of acute kidney injury.
• New or worsening depression, mood changes, or suicidal ideation — discontinue and contact your prescriber; if in acute crisis, call or text 988.
• Severe hypoglycaemia in patients also on sulfonylureas or insulin — 911 or immediate glucose administration for severe episodes; a dose reduction of the co-therapy is usually needed at Saxenda start.
• Suspected over-injection or accidental pediatric ingestion of a pen — poison control 1-800-222-1222 (US) immediately.

How this connects to the rest of the site

Saxenda sits at the crossroads of the GLP-1 cluster, the adolescent obesity cluster, and the access-limited prescribing conversation. For the broader medication landscape, see prescription weight loss medications and weight loss drug safety. For the GLP-1 class overview and comparisons, see GLP-1 weight loss overview, GLP-1 medications compared, GLP-1 cost and insurance, semaglutide vs tirzepatide, and Ozempic vs Wegovy. For the individual drug comparators, see Wegovy for weight loss, Ozempic for weight loss, Zepbound for weight loss, Mounjaro for weight loss, semaglutide for weight loss, and tirzepatide for weight loss. For the pre-GLP-1 orals, see Contrave for weight loss, Qsymia for weight loss, and phentermine for weight loss. For adolescent care, see adolescent and teen weight management. For diabetes overlap, see diabetes and weight loss. For the stopping-the-drug conversation, see rebound weight gain after stopping GLP-1.

Bottom line

Saxenda is not the strongest GLP-1 on the market — Wegovy will beat it on the scale by roughly a factor of 2.5, and Zepbound by roughly a factor of 3. What Saxenda is, is the drug that opened the modern obesity-medicine era in 2014, the only GLP-1 FDA-approved for adolescents 12+, the class member with the longest post-approval real-world safety record, and a legitimate second-choice option when the newer weekly agents are back-ordered, uncovered, or contraindicated. The daily injection burden and the tolerability curve during titration are the two friction points that determine whether it works for a given patient; the FDA week-16 stop rule keeps the drug from being continued indefinitely at sub-response, and the discontinuation-and-regain conversation belongs at the start of therapy rather than at the end. When those constraints fit, the roughly 6–8% mean weight loss it delivers — layered on top of the calorie-deficit and behavioural work that everything downstream depends on — is a real, useful, and durable result.

Saxenda FAQ

How much weight loss should I expect? Roughly 6–8% at 56 weeks on 3.0 mg (Pi-Sunyer 2015 SCALE Obesity; Davies 2015 SCALE Diabetes) — about 40% of Wegovy’s effect and 30% of Zepbound’s.

Who is it best for? Adolescents 12+ (only GLP-1 with an FDA obesity approval in that age group), adults for whom Wegovy or Zepbound are back-ordered or unaffordable, and patients whose prescriber prefers a shorter-half-life agent for tolerability.

Who should not take it? Anyone with a personal or family history of medullary thyroid cancer or MEN2, active pancreatitis, severe GI disease, or during pregnancy — and anyone already on a GLP-1 or GLP-1/GIP agent.

How is it dosed? Weekly titration over 4 to 5 weeks: 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg daily subcutaneous.

What is the FDA stop rule? Discontinue if less than 4% weight loss at week 16 (FDA 2014 labelling).

How does it compare head-to-head with Wegovy? STEP-8 (Rubino 2021, JAMA): 6.4% on liraglutide vs 15.8% on semaglutide at 68 weeks — a roughly 2.5-fold difference favouring semaglutide.

Will I regain weight after stopping? Roughly two-thirds of weight lost typically returns within 12 months of stopping (Aroda 2019). Plan for this at the start of therapy.